Compare CC & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CC | AVDL |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | N/A | 1996 |
| Metric | CC | AVDL |
|---|---|---|
| Price | $16.04 | $21.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | $17.33 | ★ $19.14 |
| AVG Volume (30 Days) | ★ 2.7M | 1.4M |
| Earning Date | 02-17-2026 | 03-02-2026 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,837,000,000.00 | $248,517,000.00 |
| Revenue This Year | $3.34 | $65.47 |
| Revenue Next Year | $4.07 | $30.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.03 | ★ 79.88 |
| 52 Week Low | $9.13 | $6.38 |
| 52 Week High | $20.12 | $23.57 |
| Indicator | CC | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 71.72 | 59.40 |
| Support Level | $14.76 | $21.45 |
| Resistance Level | $16.58 | $21.60 |
| Average True Range (ATR) | 0.79 | 0.07 |
| MACD | 0.27 | -0.03 |
| Stochastic Oscillator | 86.84 | 70.73 |
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.